SCHEMBL5467743

SCHEMBL5467743

CC(C)(C)C1COc2ccccc2N1C(=O)CN1CCc2cccc(O)c2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
ALDH1A1 P00352 5/20 0.45
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 1/20 0.38
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453534 0.88 KMT2A (0.45) MEN1KMT2ACRHBPCRHR2ALDH1A1
SCHEMBL5456228 0.85 HPGD (0.56) ALDH1A1LMNASMN1; SMN2HPGDNPSR1
SCHEMBL5456346 0.76 ALDH1A1 (0.52) MEN1KMT2AALDH1A1CYP2C9CYP2C19
SCHEMBL5459349 0.76 TP53 (0.43) MEN1KMT2AALDH1A1LMNATP53
SCHEMBL5456330 0.75 ALDH1A1 (0.46) ALDH1A1POLBL3MBTL1DRD2DRD4
SCHEMBL5453468 0.75 LMNA (0.53) KMT2AALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL5451186 0.73 SMN1; SMN2 (0.46) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL5447846 0.73 LMNA (0.51) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL5453789 0.73 NPC1 (0.46) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL5453866 0.72 SMN1; SMN2 (0.43) KMT2AALDH1A1LMNASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043024-A1 Azacyclic compounds as inhibitors of sensory neurone specific channels IONIX PHARMACEUTICALS LIMITED (GB) 2007-02-22 US disclosed
EP-1660454-A1 AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS Vernalis (R&D) Limited (GB) 2006-05-31 EP disclosed
WO-2005005392-A1 AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS IONIX PHARMACEUTICALS LIMITED (GB) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043024-A1 Azacyclic compounds as inhibitors of sensory neurone specific channels SCN1B, SCN1A, SCN10A MEN1 2444/4885KMT2A 2911/4885CRHBP 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.